Stockscreener 앱 받기
55.54
1.75%
0.92
시간 외 거래:
55.54
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Alpha Thalassemia Pipeline Insights 2024: Therapies, Clinical - openPR
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat
ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com
Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada
Agios Pharmaceuticals director sells shares worth $1.12 million - Investing.com India
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com India
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock By Investing.com - Investing.com UK
StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada
Agios stock soars to 52-week high, reaching $53.28 - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance
Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India
Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat
Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia
Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com
Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate
Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com
Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview: Agios Pharmaceuticals - Benzinga
Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St
Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India
Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online
Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada
Agios completes enrollment for sickle cell disease trial - Investing.com
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times
0.93%
3.56%
자본화:
|
볼륨(24시간):